Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, IL, 60611, U.S.A.
Northwestern Medicine Multidisciplinary Eczema Center, Chicago, IL, U.S.A.
Br J Dermatol. 2017 Nov;177(5):1316-1321. doi: 10.1111/bjd.15641. Epub 2017 Oct 1.
Scoring systems for assessing the signs of atopic dermatitis (AD) are complex and difficult to interpret. Severity strata are helpful to interpret these assessments properly.
To confirm previously reported strata for the Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD) and the objective component of SCORAD (oSCORAD), and to develop strata for the modified EASI (mEASI), Atopic Dermatitis Severity Index (ADSI) and body surface area (BSA) for use in adults with AD.
Skin examination was performed in 673 adolescents and adults (age ≥ 13 years) with diagnosed AD, in a dermatology practice setting. Strata were selected using an anchoring approach based on a four-point Investigator's Global Assessment of severity (clear of active skin lesions, mild, moderate or severe disease).
We determined potential severity strata for EASI (0 clear, 0·1-5·9 mild, 6·0-22·9 moderate, 23·0-72 severe; κ = 0·69), mEASI (0-0·9 clear, 1-8·9 mild, 9·0-29·9 moderate, 30·0-90 severe; κ = 0·71), oSCORAD (0-7·9 clear, 8·0-23·9 mild, 24·0-37·9 moderate, 38·0-83 severe; κ = 0·70), SCORAD (0-9·9 clear, 10·0-28·9 mild, 29·0-48·9 moderate, 49·0-103 severe; κ = 0·68), ADSI (0-1·9 clear, 2-5·9 mild, 6·0-8·9 moderate, 9·0-15 severe; κ = 0·55) and BSA (0 clear, 0·1-15·9 mild, 16·0-39·9 moderate, 40·0-100 severe; κ = 0·66). oSCORAD values > 0 were found in clear skin due to the presence of xerosis, which is scored in oSCORAD. Similarly, SCORAD values > 0 were found in clear skin due to the scoring of xerosis, pruritus and sleeplessness. Similarly, mEASI and ADSI scores > 0 occurred in patients with clear skin due to scoring of pruritus.
We recommend using these strata for interpretation of their respective measures in clinical trials of AD. There are important differences between the five assessments, which profoundly impact the interpretation of their scores.
评估特应性皮炎(AD)体征的评分系统较为复杂,难以解读。严重程度分层有助于正确解读这些评估。
验证之前报道的 Eczema Area and Severity Index(EASI)、Scoring Atopic Dermatitis(SCORAD)和 SCORAD 的客观成分(oSCORAD)的分层,并为改良 EASI(mEASI)、Atopic Dermatitis Severity Index(ADSI)和体表面积(BSA)开发用于 AD 成人患者的分层。
在皮肤科实践环境中,对 673 名年龄≥13 岁的确诊 AD 青少年和成人进行了皮肤检查。使用基于四点研究者整体严重程度评估(无活动性皮损、轻度、中度或重度疾病)的锚定方法选择分层。
我们确定了 EASI(0 无皮损,0.1-5.9 轻度,6.0-22.9 中度,23.0-72 重度;κ=0.69)、mEASI(0-0.9 无皮损,1-8.9 轻度,9.0-29.9 中度,30.0-90 重度;κ=0.71)、oSCORAD(0-7.9 无皮损,8.0-23.9 轻度,24.0-37.9 中度,38.0-83 重度;κ=0.70)、SCORAD(0-9.9 无皮损,10.0-28.9 轻度,29.0-48.9 中度,49.0-103 重度;κ=0.68)、ADSI(0-1.9 无皮损,2-5.9 轻度,6.0-8.9 中度,9.0-15 重度;κ=0.55)和 BSA(0 无皮损,0.1-15.9 轻度,16.0-39.9 中度,40.0-100 重度;κ=0.66)的潜在严重程度分层。由于 oSCORAD 中存在干燥症评分,因此在无皮损皮肤中也发现了 oSCORAD 值>0。同样,由于干燥症、瘙痒和失眠评分,在无皮损皮肤中也发现了 SCORAD 值>0。类似地,由于瘙痒评分,在无皮损皮肤中 mEASI 和 ADSI 评分>0。
我们建议在 AD 的临床试验中使用这些分层来解释各自的评估结果。这五种评估方法之间存在重要差异,这极大地影响了它们评分的解读。